Cargando…
β‐Elemene Selectively Inhibits the Proliferation of Glioma Stem‐Like Cells Through the Downregulation of Notch1
Glioma is the most frequent primary central nervous system tumor. Although the current first‐line medicine, temozolomide (TMZ), promotes patient survival, drug resistance develops easily. Thus, it is important to investigate novel therapeutic reagents to solidify the treatment effect. β‐Elemene (bEL...
Autores principales: | Feng, Hai‐bin, Wang, Jing, Jiang, Hao‐ran, Mei, Xin, Zhao, Yi‐ying, Chen, Fu‐rong, Qu, Yue, Sai, Ke, Guo, Cheng‐cheng, Yang, Qun‐ying, Zhang, Zong‐ping, Chen, Zhong‐ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442766/ https://www.ncbi.nlm.nih.gov/pubmed/28297578 http://dx.doi.org/10.5966/sctm.2016-0009 |
Ejemplares similares
-
β-elemene combined with temozolomide in treatment of brain glioma
por: Zhang, Xiaomin, et al.
Publicado: (2021) -
Skp2 modulates proliferation, senescence and tumorigenesis of glioma
por: Wu, Juan, et al.
Publicado: (2020) -
Chemotherapy for gliomas in mainland China: An overview
por: SAI, KE, et al.
Publicado: (2013) -
MiR-181b sensitizes glioma cells to teniposide by targeting MDM2
por: Sun, Yan-chang, et al.
Publicado: (2014) -
Profile of nimotuzumab in the treatment of high-grade glioma
por: Yang, Qun-ying, et al.
Publicado: (2015)